Veyonda®
Working with the body to fight cancer, not against it
Veyonda®
Allowing lower, better-tolerated doses of chemotherapy and radiotherapy
Veyonda®
A disruptive technology to transform the management of cancer
Veyonda®
Aiming to move cancer treatments from extending lives to saving lives

Our Science

Veyonda is a first-in-class activator of the innate immune system. This is the system that scientists increasingly are beginning to see must be activated if a cancer is to have any chance of being permanently eradicated.

Pipeline and Clinical Trials

Establishing Veyonda as an essential adjunct to radiotherapy in the treatment of prostate cancer and discharging portfolio risk by studying Veyonda in combination with radiotherapy and non-radio therapy treatments.

Features & Upcoming Events

October 22, 2019
TechKnow Investor Roadshow - Sydney, NSW
October 24, 2019
TechKnow Investor Roadshow - Melbourne, VIC
October 25, 2019
Kalkine CEO & Investor Small - Cap Conference 2019 - Sydney, NSW
November 12-14, 2019
COSA Annual Meeting - Adelaide, SA
November 20, 2019
Noxopharm 2019 AGM - Sydney, NSW

About Cancer